Drug Profile
Pepstatin
Alternative Names: Pepstatin ALatest Information Update: 18 Nov 2003
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Oligopeptides
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Nov 2003 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 30 Jul 1998 No-Development-Reported for Cancer in Italy (Unknown route)
- 28 Dec 1994 Preclinical development for Cancer in Italy (Unknown route)